Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
      • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Multiple Sclerosis
      • Systemic Sclerosis
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Eligibility


Research Spotlight
  • New scoring system offers HCT risk stratification for patients with myelofibrosis

    April 2019

  • Review: Scientific advances in myelodysplastic syndromes

    March 2019

  • Geriatric assessment and targeted interventions recommended for older patients undergoing allogeneic HCT

    February 2019

  • Transplant Indications and Outcomes
  • Eligibility
  • Email
  • Print This Page

Related Resources

  • Referral Timing Guidelines
  • Disease Indications & Outcomes
  • Unrelated Donor Search
  • Presentation Slides

Patient Resources

  • Transplant Basics Booklet
  • Transplant Basics Videos

Patient Eligibility for HCT

Identifying and evaluating patients who may benefit from hematopoietic cell transplantation (HCT) involves many factors, including overall health, prior therapies, age, disease, and disease stage. If an allogeneic transplant is being considered, it is important to identify available HLA-matched related donors, unrelated donors, or cord blood units as soon as possible.

Clinical Factors

Patients under consideration for HCT require a thorough evaluation performed by a transplant physician. A comprehensive pre-transplant evaluation should:

  • Determine the patient's health and performance status
  • Assess the patient's disease status
  • Guide the informed consent process
  • Identify any psychosocial issues that would interfere with the transplant procedure/recovery [1]

Health and Performance Status

Well-established health and performance status criteria to assess patient eligibility for HCT include:

  • Age
  • Karnofsky performance score
  • Left ventricular ejection fraction
  • Pulmonary function test; forced vital capacity
  • Diffusion capacity (DLCO)
  • Kidney function
  • Liver function
  • Mental health [2,3]

Recent research has shown that age alone should not be a determinant for HCT eligibility. [4,5] Transplant physicians therefore generally do not set an upper age limit for transplant and instead assess HCT eligibility on other clinical factors such as presence of co-morbidities and geriatric/frailty assessments. [4,6]

HCT comorbidity index

For more than a decade, transplant physicians have been using the HCT comorbidity index (HCT-CI) to evaluate HCT candidates. The HCT-CI measures the prevalence and severity of comorbidities in 17 organs. It is useful in assessing the suitability of HCT for patients, and it can also provide valuable prognostic information after HCT. [7,8]

Assessing patient eligibility using an HCT-specific tool is important because research has shown that physical function and co-morbidities, and not chronological age alone, should be considered when determining eligibility for transplant. [9] Therefore, many older patients — once considered by many transplant centers to be ineligible due to chronologic age — may in fact now be candidates for HCT.

The Fred Hutchinson Cancer Research Center has made available an online HCT-CI calculator.

Disease stage, previous treatments (chemotherapy/radiation), infectious disease, and transfusion history can also have a significant impact on HCT outcomes. Research shows that early referral is an important step that can affect survival.

Donor Factors

Three hematopoietic cell sources are used in HCT: bone marrow, peripheral blood stem cells (PBSC), and umbilical cord blood. Each source in an allogeneic transplant can come from a related or unrelated donor or cord blood unit. Most autologous transplants use PBSC for ease of collection of the cells and a more rapid hematopoietic recovery.

Recent outcome studies have demonstrated that related and unrelated donor transplant outcomes are comparable in many patient populations. Therefore, lack of a related donor should not preclude referral for a transplant consultation. [10]

Currently, the chance of having a matched, available donor on the Be The Match Registry®, ranges from 29-79% depending on patient ethnic background. Because appropriate planning and early donor identification are critical for optimal outcomes, early referral for a transplant consultation is appropriate, even for patients who ultimately may never need HCT.

Other (Non-Clinical) Factors

A psychosocial evaluation is important to assessing a patient's ability to undergo a transplant. The primary goal of the assessment is to manage any psychosocial issues that would interfere with the transplant procedure and the recovery phase. [1-3]

Due to the often lengthy recovery period, most transplant centers require a caregiver to advocate for the patient and to be available to assist the patient during and after transplant.

Transplant Center-Specific Requirements

Transplant centers in our Network each have criteria for the kinds of transplants performed, and diseases and ages treated. Access individual U.S. transplant center information and outcomes.


References

  1. Blume KG, Krance RA. The evaluation and counseling of candidates for hematopoietic cell transplantation. In: Appelbaum FR, Thomas ED, eds. Thomas' Hematopoietic Cell Transplantation. 4th ed. Hoboken, NJ: Wiley-Blackwell; 2009: 445-460.
  2. Scott BL, Sandmaier BM. The evaluation and counseling of candidates for hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. 5th ed. Hoboken, NJ: Wiley-Blackwell; 2016: Chapter 29. Access
  3. Fedele R, Salooja N, Martino M. Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2016; 16(11): 1361-1372. Access
  4. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014; 32(29): 3249-3256. Access
  5. Rashidi A, Ebadi E, Colditz GA, DiPersio JF. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. Biol Blood Marrow Transplant. 2016; 22(4): 651-657. Access
  6. Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018; 131(5): 515-524. Access
  7. Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013; 121(15): 2854-2863. Access
  8. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8): 2912-2919. Access
  9. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010; 28(11): 1878-1887. Access
  10. Saber W, Opie S, Rizzo JD, et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012; 119(17): 3908-3916. Access
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright